NEWLY APPROVED HEAD AND NECK CANCER TREATMENT IMPROVES CARE FOR FIRST TIME IN MORE THAN 20 YEARS
The National Institute for Health and Care Excellence (NICE) has recommended an immunotherapy to treat advanced head and neck cancer for use on the NHS in England. In final draft guidance, published on 24 March 2026, NICE approved pembrolizumab (Keytruda; MSD), an IV infusion for patients with resectable locally advanced head and neck squamous cell […]
MRNA CANCER VACCINES
Personalised mRNA cancer vaccines are still in development. They are designed to teach and activate the body’s immune system to recognise, hunt down and attack cancer cells. Cancer vaccines are a class of immunotherapy that is still in development. No cancer vaccines are currently licenced for use in standard cancer care – patients can only access […]
NATURAL KILLER CELLS AND CANCER
NATURAL KILLER CELLS AND CANCER Natural Killer (NK) cells play a crucial role in the immune system’s defense against cancer. They induce cancer cell death primarily through two mechanisms: apoptosis and necrosis. Apoptosis is a programmed, non-infiammatory form of cell death, while necrosis is a more abrupt and inflammatory process. In many cases, NK cells […]
T CELL DYNAMICS WITH NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER
T CELL DYNAMICS WITH NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER Neoadjuvant immune-checkpoint inhibitors (ICIs) have been shown to be safe with promising early trial results in patients with locally advanced, resectable human papillomavirus-unrelated head and neck squamous cell carcinoma. Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in […]